Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tracks how well secukinumab works for painful skin condition in daily life

NCT ID NCT06517732

Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 107 adults in Russia with moderate to severe hidradenitis suppurativa (a chronic skin condition causing painful lumps) who are taking secukinumab as part of their normal care. Researchers will track how many patients see a 55% reduction in disease severity over time, using a standard scoring system. The goal is to see how well the drug works in real-world settings, outside of controlled clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
secukinumab
What this could lead to
If successful, this study could confirm that secukinumab works well in everyday practice for people with hidradenitis suppurativa, supporting its wider use.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It only includes patients already prescribed the drug, and the sample size is small (107 people).

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

107 people

The number who actually took part.

Started

Jul 2024

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with moderate to severe Hidradenitis Suppurativa commencing treatment with secukinumab

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients who provide written informed consent form (ICF) to participate in the study. 2. Male and female. 3. ≥ 18 years old. 4. Diagnosis of moderate or severe HS (Hurley stage and IHS4). 5. Patient who initiated treatment with secukinumab no longer than 4 weeks prior to written ICF. 6. Decision for secukinumab prescription was made by the attending physician according to the approved national label during routine clinical practice, regardless of study participation. Exclusion Criteria: 1. Any medical or psychological condition that may prevent the study participation, based on practitioners' decision-making. 2. Participation in an ongoing clinical trial. 3. Known or suspected severe hypersensitivity for secukinumab, formulation excipients, or injection device components (i.e., latex). 4. Clinically significant infection exacerbation, including active tuberculosis. 5. Patients with active inflammatory bowel disease (IBD). 6. Age \<18 years. 7. Pregnancy and breastfeeding. 8. Patients who received any vaccine within 4 weeks prior to secukinumab initiation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hidradenitis suppurativa are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hidradenitis suppurativa

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hidradenitis suppurativa

Contacts and locations

Locations

  • Novartis Investigative Site

    Izhevsk, 426039, Russia

  • Novartis Investigative Site

    Kaliningrad, 236016, Russia

  • Novartis Investigative Site

    Kaliningrad, 236029, Russia

  • Novartis Investigative Site

    Kazan', 420012, Russia

  • Novartis Investigative Site

    Kemerovo, 650025, Russia

  • Novartis Investigative Site

    Krasnodar, 350020, Russia

  • Novartis Investigative Site

    Moscow, 107076, Russia

  • Novartis Investigative Site

    Moscow, 119881, Russia

  • Novartis Investigative Site

    Moscow, 123182, Russia

  • Novartis Investigative Site

    Moscow, 129110, Russia

  • Novartis Investigative Site

    Nizhny Novgorod, 603950, Russia

  • Novartis Investigative Site

    Penza, 440052, Russia

  • Novartis Investigative Site

    Saint Petersburg, 197022, Russia

  • Novartis Investigative Site

    Samara, 443079, Russia

  • Novartis Investigative Site

    Saratov, 410028, Russia

  • Novartis Investigative Site

    Stavropol, 355020, Russia

  • Novartis Investigative Site

    Tula, 300053, Russia

  • Novartis Investigative Site

    Ufa, 450010, Russia

  • Novartis Investigative Site

    Yakutsk, 677000, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.